Skip to main content
. 2015 May 12;4(2):56–77. doi: 10.5501/wjv.v4.i2.56

Table 1.

Antiretroviral drugs class

Antiretroviral class Generic name drug Trade name/manufacturer/approval (yr)
Nucleos(t)ide reverse transcriptase inhibitors Abacavir (ABC) Ziagen® ViiV Healthcare (1998)
Didanozine (ddl) Videx® Bristol-Myers Squibb Co. (1991)
Emtricitabine (FTC) Emtriva® Gilead Sci. (2003)
Lamivudine (3TC) Epivir® GlaxoSmithKline (1995)
Stavudine (d4T) Zerit® Bristol-Myers Squibb Co. (1994)
Tenofovir (TDF) Viread® Gilead Sci. (2001)
Zidovudine (AZT) Retrovir® ViiV Healthcare (1987)
Zalcitabine (ddC) Hivid® Roche (1992)
Non-nucleoside reverse transcriptase inhibitors Delavirdine (DLV) Rescriptor® Pfizer (1997)
Efavirenz (EFV) Sustiva® Bristol-Myers Squibb Co. (1998)
Stocrin® Merck Sharp, Dohme (1998)
Nevirapine (NVP) Viramune® Boehringer Ingelheim (1996)
Etravirine (ETR) Intelence® Janssen-Cilag (2008)
Rilpivirine (RPV) Edurant® Janssen-Cilag (2011)
Protease inhibitors Amprenavir Agenerase® GlaxoSmithKline (1999)
Atazanavir Reyataz® Bristol-Myers Squibb Co. (2003)
Darunavir Prezista® Janssen-Cilag (2006)
Fosamprenavir Lexiva® ViiV Healthcare (2003)
Indinavir Crixivan® Merck and Co. (1996)
Lopinavir Kaletra® Abbott (2000)
Nelfinavir Viracept® ViiV Healthcare (1997)
Ritonavir Norvir® AbbVie Inc. (1996)
Saquinavir Invirase® Roche (1995)
Tipranavir Aptivus® Boehringer Ingelheim (2005)
Fusion inhibitors Enfuvirtide, T-20 Fuzeon® Hoffmann La Roche (2003)
Integrase strand transfer inhibitors Dolutegravir (DTG) Tivicay® GlaxoSmithKline (2013)
Elvitegravir (EVG) Stribild® Gilead Sci. (2012)
Raltegravir (RAL) Isentress® Merck and Co. (2007)
Entry inhibitors (CC chemokine receptor 5 antagonists) Selzentry Maraviroc® Pfizer (2007)